Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
23 Abril 2024 - 9:00AM
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that
it will release its first-quarter 2024 financial results
on Tuesday, May 7, 2024, prior to the open of the
U.S. financial markets.
Following the announcement, Madrigal’s management will host a
live webcast at 8 a.m. Eastern Time to review the Company’s
financial and operating results.
The live webcast may be accessed at the Investor Relations
section of the Madrigal Pharmaceuticals website. To ensure a
timely connection, it is recommended that participants register at
least 15 minutes prior to the scheduled webcast.
The webcast will be available approximately two hours after the
live webcast.
About Madrigal PharmaceuticalsMadrigal
Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company
pursuing novel therapeutics for nonalcoholic steatohepatitis
(NASH), a liver disease with high unmet medical need. Madrigal’s
medication, Rezdiffra (resmetirom), is a once-daily, oral,
liver-directed THR-β agonist designed to target key underlying
causes of NASH. For more information, visit
www.madrigalpharma.com.
Investor ContactTina Ventura, Madrigal
Pharmaceuticals, Inc., IR@madrigalpharma.com
Media ContactChristopher Frates, Madrigal
Pharmaceuticals, Inc., media@madrigalpharma.com
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024